Background: There has been a revolution in the treatment of hepatitis C virus (HCV) infection since the introduction of new direct-acting antivirals agents (DAAs) in 2014. About 95% of the patients have a sustained virological response (SVR) after 12 weeks with DAAs. The aim of this study was to evaluate the SVR after 12 weeks of treatment with the combination of sofosbuvir (SOF)/ledipasvir (LDV) +/-ribavirin (RBV) among a cohort of Cameroonian HCV carriers.Methods: This was a cross-sectional study in HCV treatment centers in Cameroon health facilities in Yaounde and Douala. It focused on patients with chronic HCV of genotypes 1 and 4 treated with the SOF/ LDV +/-RBV combination for 12 weeks. The virological response after 4 and 12 weeks of treatment was determined. SVR indicating recovery was determined 12 weeks after the end of treatment (SVR12).
Results:A total of 111 patients with chronic HCV were included. There was female predominance with a proportion of 58.6%. The average age of the patients was 58.8 ± 8.2 years. Genotype 1 was the most frequent with 68.5% of the cases. The SVR was 93.7% (95% CI (87.4% -97.4%)) regardless of protocol and genotype. HCV infection without cirrhosis was associated with good SVR (aOR = 0.1, 95 CI (0.1 -0.9), P = 0.02). The most common clinical adverse reaction was asthenia with 12.5% (n = 10).
Conclusions:The SVR12 in Cameroonian patient infected with HCV genotypes 1 and 4 treated with the combination SOF/LDV +/-RBV was 93.7%. Cirrhosis is a factor of poor response.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.